Protocol Ledger

NCT04493424 · Phase II · TERMINATED

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Interventional Phase II clinical trial protocol NCT04493424 sponsored by Boehringer Ingelheim in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-04 Enrollment: 108 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04493424
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)108 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04493424
Protocol FieldVerified Registry Value
NCT IdentifierNCT04493424
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment108 participants (ACTUAL)
Registered Start Date2020-09-04
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04493424
Hospital Research SiteLocationSite Profile
University of Pittsburgh Medical CenterPittsburgh, PAOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->
Royal Melbourne HospitalParkville, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI